AbCellera Plans Late-Stage Development for ABCL635 in 2027 Following Positive Phase II Results
AbCellera Biologics Inc. (ABCL) reported a transformative third quarter, highlighted by positive Phase II clinical results for its NK3R antibody candidate, ABCL635. CEO Carl L. Hansen indicated that the company intends to initiate late-stage development for this asset in 2027. In addition to clinical progress, management provided reassurance regarding the company's financial stability. AbCellera stated it maintains sufficient liquidity to fund operations for at least the next three years, providing a runway as it advances its therapeutic pipeline.